Background: To explore the current clinical management of early-stage breast cancer (BC) patients, identify areas of controversy, and interrogate how treating physicians implement latest advances.
introduction
Breast cancer (BC) represents the most commonly diagnosed female malignancy and is the most frequent cause of cancerrelated deaths among women in the Western world. Thanks to screening programs and improved sensitivity of radiographic modalities, more women are diagnosed with early-stage disease, resulting in an enhanced chance of cure. The clinical management of early-stage BC requires a multidisciplinary approach involving radiologists, pathologists, surgeons, and medical oncologists [1] . BC oncology represents one of the most dynamically evolving fields of oncology, with groundbreaking recent developments. These include the molecular characterization of the disease, accurate prognostication with the implementation of genomic signatures, advances in (neo)-adjuvant cytotoxic chemotherapy and endocrine treatment, and the implementation of molecularly targeted agents to treat early-stage HER2-positive disease.
Detailed guidelines regarding evidence-based clinical management of early-stage BC patients have been issued by major oncology societies, such as the European Society for Medical Oncology (ESMO) [2] , American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN) [3] . Another long-lived initiative, the St Gallen International Expert Consensus, aims to develop expert consensus guidelines for early BC by comprehensively analyzing scientific evidence from available literature [4] . Nevertheless, the uptake of new advances is not universal, with the consequence being heterogeneity in the medical management of early-stage BC patients. Additionally, level I evidence is lacking for certain areas of clinical practice, whereby the medical care provided to patients is influenced by the personal preferences of treating physicians.
The purpose of this study was to explore current clinical practice in the management of early-stage BC, to identify areas of controversies, and to interrogate how treating physicians implement latest advances. Issues related to the diagnosis and staging, local and systemic treatment modalities, and prognostication of the early BC patient population were assessed. methods questionnaire A 27-item survey was conducted (Table 1) , consisting of multiple-choice and open-ended questions. It was accompanied by a cover letter explaining the purpose of the survey. The seven first questions captured the demographic characteristics of the participants, and the remaining 20 addressed the issues of interest related to the clinical management of early-stage BC. These questions explored issues around radiologic staging (one item), molecular characterization of the disease and genomic prognosticators (three items), cytotoxic chemotherapy (five items), endocrine treatment (five items), molecularly targeted agents (five items), and other (one item). The questionnaire was constructed on the basis of a literature search conducted by a first group of the authors (DZ, FA, IBS, LP, MC). Two of the remaining authors (EDA, MPi) independently checked the item list to ensure that the most clinically relevant issues affecting the clinical management of early BC were included in the survey.
survey dissemination
The survey was disseminated according to a two-stage procedure. First, the physical dissemination took place during the ESMO Congress 2012 in Vienna, Austria, between 28 September and 2 October 2012. In order to increase the chances of reaching physicians interested in BC, we selected three BC sessions, where a total of 900 questionnaires were distributed. In a second step, the survey was electronically disseminated through targeted mailing messages to ESMO members, with a stated focus on BC. E-mails were sent directly by the ESMO Headquarters in order to maintain members' confidentiality. To improve the response rate, we used a modified Dillman technique [5] : one reminder e-mail, integrated in an ESMO Scientific Newsletter, was sent 2 weeks after the initial electronic message.
No honorarium was provided to the survey participants.
statistical analysis
All survey data were coded and entered into a common database, which was electronically transferred from ESMO Headquarters in Viganello-Lugano, Switzerland, to Institute Jules Bordet, Brussels, Belgium. Descriptive statistical analysis was undertaken using Excel software from Microsoft Office. Logistic regression analysis was carried out to explore potential associations between the demographic characteristics of the participants and replies provided. To this end, we defined what we considered as correct answers according to the evidence found in the literature. We got then binary outcome variables that were the dependent variables modeled thanks to logistic regression models. Odds ratios were estimated, using the maximum likelihood ratio method, together with 95% confidence intervals. Significance of odds ratios was assessed; P < 0.05 was used to declare statistical significance.
results response rates and sample characteristics
In total, 512 physicians from 79 different countries participated in the survey, with 465 (91%) returning fully completed questionnaires, which are reported here. A total of 219 fully completed questionnaires were returned from the onsite dissemination, with the remaining 246 coming from the electronic dissemination. The demographic characteristics of the participants can be found in Table 2 . As is evident, multinational representation from all medical disciplines involved in the management of early-stage BC was achieved.
responses radiologic staging
The radiologic modalities applied for staging of BC at diagnosis reported in descending order of frequency were as follows: 
molecular characterization of BC and genomic prognosticators
Regarding molecular characterization of early-stage BC, the estrogen receptor (ER)/progesterone receptor (PgR)/HER2 triplet was mentioned to be necessary for therapeutic decisions by 451 (97%) participants, with Ki67 being required by 410 (88.2%).
Additional molecular markers mentioned to be necessary for therapeutic decisions at diagnosis were p53 (53; 11.4%); cytokeratins (43; 9.2%); EGFR (36; 7.7%); and PIK3CA mutational status (26; 5.6%). Genetic tests considered to be useful in determining the benefit of adjuvant therapy in any individual BC patient were as follows: oncotypeDX® (237; 51%); none (190; 40.9%); MammaPrint® (95; 20.4%); Genomic Grade Index (GGI) (20; 4.3%); PAM50 (20; 4.3%); and other genetic tests mentioned by participants spontaneously (15; 3.2%).
Proliferation markers used to determine the benefit of adjuvant therapy in patients with HER2−/ER+ node-negative BC were histological grade (410; 88.2%); KI67 (394; 84.7%); mitotic index (106; 22.8%); none (12; 2.6%); and other parameters (25; 5.4%). tumor size ≥5 cm (83; 17.8%); HER2 positivity (61; 13.1%); and Ki67 >30% (52; 11.2%). Of note, 165 (35.5%) of the participants replied that they never administered dose-dense chemotherapy, while 14 (3%) indicated that they always did.
As regards fertility preservation techniques used for young BC patients (<35 years) undergoing adjuvant chemotherapy, the following was reported: Luteinizing-hormone-releasing hormone (LHRH) agonists (161; 34.6%); oocyte/embryo cryopreservation (155; 33.3%); ovarian tissue cryopreservation (64; 13.8%); avoidance of alkylating agents (26; 5.6%); and no protective measures (59; 12.7%).
Notably, physicians were divided about their approaches to treatment according to nodal involvement: 253 (54.4%) survey participants chose different adjuvant chemotherapy regimens, while 212 (45.6%) participants opt for the same chemotherapy regimen.
The majority of participants (312; 67.1%) polled in this questionnaire do not routinely administer platinum compounds as part of (neo)-adjuvant therapy in triple-negative BC whereas 87 (18.7%), 53 (11.4%), and 13 (2.8%) replied that they use carboplatin, cisplatin, and other platinum compounds, respectively.
endocrine treatment
The participants were asked to identify the optimal adjuvant endocrine therapy for postmenopausal patients with hormone receptor (HR)-positive, node-positive BC. Overwhelmingly, the majority of respondents (352; 75.7%) considered aromatase inhibitors (AI) for 5 years to be the optimal therapy. The remainder of those surveyed deemed the following therapies to be the ideal treatment choice: tamoxifen for 2-3 years followed by AI for 2 years (175; 37.6%); tamoxifen for 5 years followed by AI for 5 years (106; 22.8%); and AI for 2-3 years followed by tamoxifen for 2 years (105; 22.6%). Only 40 (8.6%) participants regarded tamoxifen for 5 years to be appropriate, and 22 (4.7%) chose other options.
Participants identified the following as optimal therapy for HR-positive, node-negative BC: AI for 5 years (275; 59.1%); tamoxifen for 2-3 years followed by AI for 2 years (255; 54.8%); tamoxifen for 5 years (144; 31%); AI for 2-3 years followed by tamoxifen for 2 years (121; 26%); tamoxifen for 5 years followed by AI for 5 years (42; 9%); and other endocrine treatment regimens (6; 1.3%).
The role of AIs in postmenopausal BC was explored by asking whether this population of patients should always receive an AI as part of their adjuvant endocrine treatment. The majority of participants (320; 68.8%) replied yes; 72 (15.5%) felt this was mandatory only in the presence of high-risk factors (i.e. ≥4 positive nodes, high grade, large tumors); 62 (13.3%) replied no; and 11 (2.4%) gave other replies.
The duration of LHRH agonist administration in premenopausal patients with HR-positive BC was also assessed, with the following replies received: 1 year (12; 2.6%); 2 years (194; 41.7%); 3 years (74; 15.9%); 5 years (83; 17.8%); and other duration (15; 3.3%). Eighty-seven (18.7%) participants replied that they never administer LHRH agonists in this setting.
Lastly, participants were asked to identify their preferred endocrine treatment of a premenopausal patient with HER2-positive, HR-positive, node-negative BC, with the following replies: tamoxifen (211; 45.4%); tamoxifen plus LHRH agonist (204; 43.9%); AI plus LHRH agonist (44; 9.4%); and other choice (6; 1.3%).
molecularly targeted agents
The participants were also asked to identify which patients they viewed as candidates for adjuvant bisphosphonate treatment, independently of reimbursement issues: no patients (218; 46.9%), ER-positive postmenopausal women (138; 29.7%), ER-positive premenopausal women on LHRH agonist plus tamoxifen treatment (67; 14.4%), and, lastly, any ER-positive patient or any patient (21; 4.5% each).
Regarding the sequence of adjuvant trastuzumab administration, the most frequent response was that trastuzumab was given concurrently with taxanes, following anthracycline-based chemotherapy (366; 78.7%). Other responses indicated that trastuzumab was administered after anthracycline-based chemotherapy (58; 12.5%), or as part of the TCH regimen (docetaxel, carboplatin, trastuzumab) (34; 7.3%). Finally, seven participants (1.5%) responded that trastuzumab was not available in their countries.
To the question whether lapatinib was considered to be an alternative to adjuvant trastuzumab treatment in case of contraindications to trastuzumab, the following replies were provided: no (270; 58%); yes (118; 25.4%); yes, but only in the case of HRnegative and node-positive disease (50; 10.8%); yes, but only in the case of node-positive disease (11; 2.4%); and yes, but only in the case of HR-negative BC (8; 1.7%).
Regarding administration of adjuvant trastuzumab for HER2-positive tumors <1 cm, 237 (51%) participants supported its use even in the absence of node infiltration; 161 (34.6%) would do so only in the presence of risk factors (grade 3 and/or HR negativity); and 67 (14.4%) would not administer trastuzumab in this setting.
Lastly, the participants were asked to identify clinical situations in which they would administer bevacizumab in the neoadjuvant setting, irrespectively of reimbursement issues, and they replied the following: never (340; 73%); for TNBC (115; 24.8%); for HER2-positive BC (6; 1.3%); and for HR-positive BC (4; 0.9%).
other Participants were asked to respond how they would treat a patient with 'good-risk' ductal carcinoma in situ (DCIS), i.e. ER/ PgR-positive, postmenopausal, 1 cm on mammogram, low nuclear grade. The following replies were provided: lumpectomy plus whole-breast irradiation (RT) with or without tamoxifen 
logistic regression analysis
No significant associations were found between demographic characteristics of the participants and the responses they provided.
discussion
Although there has been great progress achieved in all aspects of the clinical management of patients with early-stage BC, there are a number of issues still to be resolved. Level I research evidence is a prerequisite for introducing changes into standard medical practice; however, such evidence is not universally available (supplementary Table S1 , available at Annals of Oncology online). Thus, we decided to conduct a survey of physicians involved in the treatment of patients with early-stage BC, with the objective to explore their preferences and/or practices for areas in which clarity about treatment standards is lacking. The results we obtained showed wide variability among the respondents' practices and preferences. However, it must be emphasized that this heterogeneity does not necessarily correspond to 'right' or 'wrong' clinical practice. This can be best exemplified by the variability in replies we received about preferences regarding adjuvant endocrine therapy: the results of reported phase III randomized trials justify this variability, since issues such as the optimal duration of treatment remain unresolved.
A limitation of our study is that the findings about variability in clinical practice and preferences do not derive from an objective analysis; rather, these are based on self-reported data, for which evidence exists that may bias response patterns [6] . However, more recently, a systematic review concluded that clinicians' behavior can be predicted by self-reported intentions [7] . A second possible limitation of our survey is the low overall response rate, especially of the questionnaires distributed to 8000 members during the electronic dissemination phase. However, we consider it highly unlikely that these two factors explain the heterogeneity of replies we received.
A strength of our survey is its size: a large number of clinical practitioners involved in the management of patients with early BC responded to our survey, covering a wide spectrum of medical professionals in terms of extent of experience, working environment, and geographic region. The predominance of medical oncologists responding should also be viewed as strength considering the content of the questions asked. Moreover, the procedure we followed to disseminate our survey increased the chances that the responders are currently actively involved in the clinical management of BC patients, thus making the results more relevant.
Another contribution of our study stems from our crosscomparison of the issues explored by it with the currently existing guidelines (supplementary Table S1 , available at Annals of Oncology online). This analysis showed that existing guidelines do not cover areas such as indications for dose-dense adjuvant chemotherapy, use of bevacizumab in the neoadjuvant setting, and administration of bisphosphonates as part of adjuvant treatment of early-stage BC patients, which corresponds well with the heterogeneous replies we received to some questions. Other research has already acknowledged the potential of guidelines to diminish unwanted variation in clinical practice [8] . Furthermore, feedback given by practitioners has been already assessed and found to be both feasible and helpful in the process of guidelines generation [9] .
In conclusion, our survey captures the current variation in the beliefs of medical professionals about multiple issues related to management of early-stage BC patients. This variation reflects differential interpretation of currently existing scientific evidence (including in some cases lack of clear evidence), which in turn results in differential implementation in clinical practice. Our results identifying areas of controversy in beliefs about clinical practice can be exploited by oncology societies to generate 'tailored' educational tools that can improve standardization in the clinical management of patients with early-stage BC. 
